Report cover image

Global Gemcitabine Hydrochloride Market 2024-2028

Publisher TechNavio
Published Jul 12, 2024
Length 132 Pages
SKU # INF19115176

Description

Global Gemcitabine Hydrochloride Market 2024-2028


Global Gemcitabine Hydrochloride Market 2024-2028

The gemcitabine hydrochloride market is forecasted to grow by USD 323.8 mn during 2023-2028, accelerating at a CAGR of 7.08% during the forecast period. The report on the gemcitabine hydrochloride market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing cancer population drive market growth, growing preference for chemotherapy drugs in developing countries, and approval of new drugs fuels market growth.

Technavio's gemcitabine hydrochloride market is segmented as below:
  • By Type
  • Generic
  • Branded
  • By Geographical Landscape
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the robust r and d activities fueling pipeline as one of the prime reasons driving the gemcitabine hydrochloride market growth during the next few years. Also, novel treatment options coupled with new applications and increasing inorganic growth strategies likely to fuel market growth will lead to sizable demand in the market.

The report on the gemcitabine hydrochloride market covers the following areas:
  • Gemcitabine hydrochloride market sizing
  • Gemcitabine hydrochloride market forecast
  • Gemcitabine hydrochloride market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gemcitabine hydrochloride market vendors that include Apotex Inc., Biocon Ltd., Cipla Inc., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., Fresenius Kabi AG, Ingenus Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Lianyungang Jinkang Pharmaceutical Technology Co. Ltd., Merck KGaA, Nichi Iko Pharmaceutical Co. Ltd., Pfizer Inc., Shilpa Medicare Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.. Also, the gemcitabine hydrochloride market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

132 Pages
    • Market overview
    • Market ecosystem
    • Market characteristics
    • Value chain analysis
    • Market definition
    • Market segment analysis
    • Market size 2023
    • Market outlook: Forecast for 2023-2028
    • Global Gemcitabine Hydrochloride Market 2018 - 2022
    • Type segment analysis 2018 - 2022
    • Geography segment analysis 2018 - 2022
    • Country segment analysis 2018 - 2022
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
    • Market segments
    • Comparison by Type
    • Generic - Market size and forecast 2023-2028
    • Branded - Market size and forecast 2023-2028
    • Market opportunity by Type
    • Customer landscape overview
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2023-2028
    • Europe - Market size and forecast 2023-2028
    • Asia - Market size and forecast 2023-2028
    • Rest of World (ROW) - Market size and forecast 2023-2028
    • US - Market size and forecast 2023-2028
    • Germany - Market size and forecast 2023-2028
    • Canada - Market size and forecast 2023-2028
    • China - Market size and forecast 2023-2028
    • UK - Market size and forecast 2023-2028
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Impact of drivers and challenges
    • Market opportunities/restraints
    • Overview
    • Competitive Landscape
    • Landscape disruption
    • Industry risks
    • Companies profiled
    • Market positioning of companies
    • Apotex Inc.
    • Biocon Ltd.
    • Eli Lilly and Co.
    • Fresenius Kabi AG
    • Intas Pharmaceuticals Ltd.
    • Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
    • Nichi Iko Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Scope of the report
    • Inclusions and exclusions checklist
    • Currency conversion rates for US$
    • Research methodology
    • Data procurement
    • Data validation
    • Validation techniques employed for market sizing
    • Data synthesis
    • 360 degree market analysis
    • List of abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us